Amanda H Corbett
Affiliation: University of North Carolina
- Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post-partum: results of the BAN StudyAmanda H Corbett
The University of North Carolina, Eshelman School of Pharmacy, Chapel Hill, NC, USA
Antivir Ther 19:587-95. 2014....
- Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian childrenAmanda H Corbett
University of North Carolina Schools of Pharmacy, Medicine and Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Antivir Ther 15:83-90. 2010....
- Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKlineAmanda H Corbett
School of Pharmacy, The University of North Carolina Hospitals, Chapel Hill 27514, USA
Curr Opin Investig Drugs 3:384-90. 2002..In September 2000 and January 2001, Merrill Lynch predicted a 2002 launch, with sales of pounds sterling 50 million in 2002, rising to pounds sterling 150 million in 2004...
- Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavirAmanda H Corbett
School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Antimicrob Agents Chemother 50:2756-61. 2006..67 [0.54 to 0.83] and 0.77 [0.59 to 0.99], respectively) compared to simultaneous administration. Additional investigations are warranted to determine the optimal dosing of FPV with LPV/RTV...
- Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxisJulie B Dumond
School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina, USA
AIDS 21:1899-907. 2007..To describe first dose and steady state antiretroviral drug exposure in the female genital tract...
- The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavirAmanda H Corbett
Schools of Pharmacy and Medicine, University of North Carolina Center for AIDS Research, University of North Carolina at Chapel Hill, 27599, USA
J Acquir Immune Defic Syndr 36:921-8. 2004..These data suggest that amprenavir/saquinavir/ritonavir may be a viable salvage regimen in heavily PI-experienced individuals. New formulations of amprenavir and saquinavir may simplify this regimen...
- Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicityMarypeace McRae
University of North Carolina at Chapel Hill, 27599 7360, USA
Pharmacotherapy 30:17-24. 2010....
- Kaletra (lopinavir/ritonavir)Amanda H Corbett
School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7360, USA
Ann Pharmacother 36:1193-203. 2002..To review the pharmacology, virology, pharmacokinetics, efficacy, safety, and clinical use of lopinavir/ritonavir (Kaletra, Abbott Laboratories)...
- Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in MalawiansKevin C Brown
University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, 3202 Kerr Hall, Chapel Hill, NC 27599 7569, USA
Pharmacogenomics 13:113-21. 2012..Genetic polymorphisms have the potential to influence drug metabolism and vary among ethnic groups. This study evaluated the correlation of genetic polymorphisms with nevirapine pharmacokinetics exposure in Malawians...
- Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometryByung Hwa Jung
Clinical Pharmacology and Analytical Chemistry Core, Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Biomed Chromatogr 21:1095-104. 2007..This method is very effective for quantifying and screening antiretroviral drugs in clinical samples with limited (50 microL) volumes...
- Self-report of current and prior antiretroviral drug use in comparison to the medical record among HIV-infected patients receiving primary HIV careEmily Suzanne Brouwer
Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA
Pharmacoepidemiol Drug Saf 20:432-9. 2011..In this study we assessed the ability of HIV-infected patients receiving care in a university infectious diseases clinic to accurately recall current and past ARVs...
- Implementation of targeted interventions to decrease antiretroviral-related errors in hospitalized patientsLindsay M Daniels
Department ofPharmacy, University of North Carolina Hospitals, Chapel Hill, NC 27514, USA
Am J Health Syst Pharm 69:422-30. 2012..The implementation and effectiveness of targeted interventions aimed at decreasing the frequency of antiretroviral-related errors in hospitalized patients with human immunodeficiency virus (HIV) are described...
- Frequency of HIV-related medication errors and associated risk factors in hospitalized patientsSonak D Pastakia
Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Purdue University, Indianapolis, IN 46202, USA
Ann Pharmacother 42:491-7. 2008..Retrospective studies of hospitalized HIV-infected patients have noted a high occurrence of drug-related errors, ranging from 5% to 30%...
- Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adultsMina C Hosseinipour
University of North Carolina Project, Lilongwe Malawi
AIDS 21:59-64. 2007..The Malawian antiretroviral program uses generic Triomune (stavudine, lamivudine, and nevirapine)...
- Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected womenSherene S Min
Schools of Medicine, University of North Carolina, Chapel Hill 27599 7360, USA
J Acquir Immune Defic Syndr 37:1577-80. 2004..Of 8 ARVs, CVF concentrations ranged from <10% to >100% of BP concentrations. These large differences in CVF penetration suggest that further research into ARV pharmacokinetics and drug efficacy in the FGT is necessary...